Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

And one more thing...
April 2019
SHARING OPTIONS:

TUCSON, Ariz.—HTG Molecular Diagnostics Inc. has amended its second precision diagnostic partnership program with QIAGEN Manchester Ltd. to extend the use of the investigational use only assay previously developed under this program and add certain activities that could be included in future companion diagnostic regulatory submissions. HTG expects this amendment—the fourth for this program—to result in revenues in the low single-digit millions due to the added activities.
 
“This amendment highlights the expanded utilization of the program assay into additional trials as well as activities getting us closer to a potential companion diagnostic,” Byron Lawson, HTG’s SVP of Pharma Partnerships, said in a press release. “We are very appreciative of the trust our Pharma partner has extended us with this expansion.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.